Genomics & Informatics

Korea Genome Organization (한국유전체학회)
권호 표지

Pharmacogenomics in Drug Discovery and Development

  • Ahn, Chul (Department of Medicine, University of Texas Medical School)
  • Published : 2007.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Pharmacogenomics is the study that examines how genetic variations affect the ways in which people respond to drugs. The ways people respond to drugs are complex traits that are influenced by many different genes. Pharmacogenomics intends to develop rational means of optimizing drug therapy, with respect to the patients' genotype, to maximize efficacy with minimal adverse drug reactions. Pharmacogenomics has the potential to revolutionize the practice of medicine, and promises to usher in an area of personalized medicine, in which drugs and drug combinations are optimized for each individual's unique genetic makeup. Indeed, pharmacogenomics is exploited as an essential step for target discovery and drug development in the pharmaceutical industry. The goal of the personalized medicine is to get the right dose of the right drug to the right patient at the right time. In this article, we will review the use of pharmacogenomics in drug discovery and development.

Keywords

References

  1. Ahn, C. and Kang, S.H. Optimal biological dose for molecularly targeted therapies. Encyclopedia of Clinical Trials. In press
  2. Cobleigh, M., Langmuir, V., Sledge, G., et al. (2003). A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Seminar. Oncol. 30, 117-124 https://doi.org/10.1053/j.seminoncol.2003.08.013
  3. DiMasi, J.A., Hansen, R.W., and Grabowski, H.G. (2003). The price of innovation: new estimates of drug development costs. Journal of Health Economics 22, 151-185 https://doi.org/10.1016/S0167-6296(02)00126-1
  4. FDA. (2004). Innovation/Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products. The Food and Drug Administration. http://www.fda.gov/oc/ initiatives/ criticalpath/whitepaper.pdf
  5. Frank, R.G. (2003). Editorial: New estimates of drug development costs. Journal of Health Economics 22, 325-330 https://doi.org/10.1016/S0167-6296(03)00002-X
  6. Ginsburg, G.S. and Angrist, M. (2006). The future may be closer than you think: a response from the Personalized Medicine Coalition to the Royal Society's report on personalized medicine. Personalized Med. 3, 119-123 https://doi.org/10.2217/17410541.3.2.119
  7. Innocenti, F., Undevia, S.D., and Iyer, L., et al. (2004). Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. Journal of Clinical Oncology 22,1382-1388 https://doi.org/10.1200/JCO.2004.07.173
  8. Jain, K.K. (2006). Challenges of drug discovery for personalized medicine. Current Opinion in Molecular Therapeutics 8, 487-492
  9. Kabbinavar, F., Hurwitz, H.I., Fehrenbacher, L., et al. (2003). Phase II randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. Journal of Clinical Oncology 21, 60-65 https://doi.org/10.1200/JCO.2003.10.066
  10. Kuhlmann, J. (2006). The applications of biomarkers in early clinical drug development to improve decision-making processes. Appropriate Dose Selection: How to Optimize Clinical Drug Development. Venitz and Sittner (ed).pp. 29-46
  11. Lazarou, J., Pomeranz, B.H., and Corey, P.N. (1998). Incidence of adverse drug reactions in hospitalized patients. J. Amer. Med. Assn. 279, 1200-1205 https://doi.org/10.1001/jama.279.15.1200
  12. Mancinelli, L., Cronin, M., and Sadée, W. (2000). Pharmacogenomics: The promise of personalized medicine. AAPS PharmSci. 2, 1-13
  13. Ozdemir, V., Williams-Jones, B., Cooper, D.M., Someya, T., and Godard, B. (2007). Mapping translational research in personalized therapeutics: from molecular markers to health policy. Pharmacogenomics 8, 177-185 https://doi.org/10.2217/14622416.8.2.177
  14. Ozdemir, V., Williams-Jones, B., Glatt, S.J., Tsuang, M.T., Lohr, J.B., and Reist, C. (2006). Shifting emphasis from pharmacogenomics to theragnostics. Nature Biotechnology 8, 942-946
  15. Personalized Medicine Coalition. (2006). The case for personalized medicine. New York, NY
  16. Phillips, K.A., Veenstra, D.L., Oren, E., Lee, K., and Sadée, W. (2001). The potential role of pharmacogenomics in reducing adverse drug reactions: A systematic review. J. Amer. Med. Assn. 286, 2270-2279 https://doi.org/10.1001/jama.286.18.2270
  17. Ratain, M.J. (2007). Personalized Medicine: Building the GPS to take us there. Clinical Pharmacology & Therapeutics 81, 321-322 https://doi.org/10.1038/sj.clpt.6100092
  18. Roden, D,M., Altman, R,B., Benowitz, N.L., et al. (2006). Pharmacogenomics: Challenges and opportunities. Annals of Internal Medicine 145, 749-757 https://doi.org/10.7326/0003-4819-145-10-200611210-00007
  19. Sconce, E., Khan, T. Wynne, H., Avery, P. Monkhouse, L., King, B., Wood, P., Kesteven, P., Daly, A., and Kamali, F. (2005).The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106, 2329-2333 https://doi.org/10.1182/blood-2005-03-1108
  20. Tamura, K. and Fukuoka, M. (2005). Gefitinib in non-small cell lung cancer. Expert Opin. Pharmacother. 6, 985-993 https://doi.org/10.1517/14656566.6.6.985
  21. Weinshilboum, R.M. and Wang, L. (2006). Pharmacogenetics and Pharmacogenomics: Development, Science, and Translation. Annu. Rev. Genom. Human Genet. 7, 223-245 https://doi.org/10.1146/annurev.genom.6.080604.162315
  22. Williams-Jones, B. and Corrigan, O.P. (2003). Rhetoric and hype: where's the 'ethics' in pharmacogenomics? Am. J. Pharmacogenomics 3, 375-383 https://doi.org/10.2165/00129785-200303060-00004
  23. Womack, C. (2005). As part of retrofitting, FDA panel votes to relabel warfarin for PGx; Is Dx far behind? Pharmacogenomics Reporter, December